NDAOPHTHALMICOINTMENT
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOROPRYL (isoflurophate) is an ophthalmic ointment approved in 1957 for treating ocular conditions, likely glaucoma or accommodative esotropia based on its cholinesterase inhibitor mechanism. It is a small-molecule irreversible acetylcholinesterase inhibitor applied directly to the eye.
LOE Approaching
This product is nearing loss of exclusivity with minimal recent spending visibility, indicating a small, mature team focused on defending market share against newer alternatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FLOROPRYL generates zero linked job postings, reflecting its minimal commercial footprint and legacy status within Merck's ophthalmic portfolio. Any role supporting this product is routine maintenance work with limited growth trajectory, visibility, or skill development.
Brand ManagerField Sales Representative
Worked on FLOROPRYL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.